Literature DB >> 9186785

B cell superantigens in HIV-1 infection.

S Müller1, H Köhler.   

Abstract

HIV-I infection affects many of the cellular components vital for the maintenance of immune homeostasis. Similar to the T cell superantigen effect on T cell expansion and depletion in AIDS. HIV components with B cell superantigenic properties could be responsible for the observed B cell activation and skewing of VH family usage. Current data on possible B cell superantigen properties of HIV proteins (gp120) are mostly based on studies describing the clonality and VH family usage of immunoglobulins in HIV infection. Various laboratories reported independently an unusual skewing of the VH-repertoire of antibodies that appears not to be random. According to these observations, an enrichment of VH1 and VH4 family-paralleled a depletion of VH3 family-utilizing anti-HIV-1 gp120 and p24 antibodies in HIV-1 infected individuals and a loss of total VH3+ Ig in patients with late stages of AIDS. Polyclonal and monoclonal (VH1, VH4, and VH5) anti-p24 and gp120 antibodies share a crossreactive idiotype (IF7). IF7 like antibodies were found in the serum of HIV-1 infected individuals, persisting in the course of infection, perhaps contributing to the depletion of VH3 Ig. Furthermore a restriction of clonal heterogeneity of anti-p24 and anti-gp120 antibodies was detected by isoelectric focusing and indicated by skewed kappa/lambda light chain isotype ratios, indicating clonal dominance of certain sets of anti-HIV-1 antibodies during infection. Taken these findings together, a strong case for the involvement of a B cell superantigen can be made, although the mechanism of B cell depletion is not fully understood.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186785     DOI: 10.3109/08830189709116524

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  7 in total

1.  X4 human immunodeficiency virus type 1 gp120 down-modulates expression and immunogenicity of codelivered antigens.

Authors:  Avi-Hai Hovav; Michael Santosuosso; Maytal Bivas-Benita; Andre Plair; Alex Cheng; Mazal Elnekave; Elda Righi; Tao Chen; Satoshi Kashiwagi; Michael W Panas; Shi-Hua Xiang; Karina Furmanov; Norman L Letvin; Mark C Poznansky
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

2.  Effects of human immunodeficiency virus encephalitis and drug abuse on the B lymphocyte population of the brain.

Authors:  Iain C Anthony; Dorothy H Crawford; Jeanne E Bell
Journal:  J Neurovirol       Date:  2004-06       Impact factor: 2.643

3.  HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells.

Authors:  Nancy P Y Chung; Katie Matthews; Per Johan Klasse; Rogier W Sanders; John P Moore
Journal:  J Immunol       Date:  2012-10-24       Impact factor: 5.422

4.  Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease.

Authors:  Felix Breden; Christa Lepik; Nancy S Longo; Marinieve Montero; Peter E Lipsky; Jamie K Scott
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

5.  B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells.

Authors:  S Moir; A Malaspina; Y Li; T W Chun; T Lowe; J Adelsberger; M Baseler; L A Ehler; S Liu; R T Davey; J A Mican; A S Fauci
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

6.  Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.

Authors:  Woodrow J Coker; Ashley Jeter; Henning Schade; Yubin Kang
Journal:  Biomark Res       Date:  2013-02-04

7.  Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region.

Authors:  Laurent Verkoczy; M Anthony Moody; T Matt Holl; Hilary Bouton-Verville; Richard M Scearce; Jennifer Hutchinson; S Munir Alam; Garnett Kelsoe; Barton F Haynes
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.